688317 之江生物
已收盘 05-12 15:00:00
资讯
新帖
简况
每周股票复盘：之江生物（688317）将召开2025年年度股东会
证券之星 · 05-10
每周股票复盘：之江生物（688317）将召开2025年年度股东会
之江生物（688317）披露2025年第三次以集中竞价交易方式回购公司股份的进展公告，5月7日股价上涨2.6%
证券之星 · 05-07
之江生物（688317）披露2025年第三次以集中竞价交易方式回购公司股份的进展公告，5月7日股价上涨2.6%
之江生物（688317）披露2025年年度股东会会议资料，5月6日股价上涨0.51%
证券之星 · 05-06
之江生物（688317）披露2025年年度股东会会议资料，5月6日股价上涨0.51%
每周股票复盘：之江生物（688317）股东户数增13.72%，一季度净利降59.27%
证券之星 · 05-02
每周股票复盘：之江生物（688317）股东户数增13.72%，一季度净利降59.27%
之江生物(688317)3月31日股东户数1.55万户，较上期增加13.72%
证券之星 · 04-29
之江生物(688317)3月31日股东户数1.55万户，较上期增加13.72%
之江生物(688317.SH)发布一季度业绩，归母净亏损2551万元
智通财经 · 04-29
之江生物(688317.SH)发布一季度业绩，归母净亏损2551万元
股市必读：之江生物（688317）4月27日披露最新机构调研信息
证券之星 · 04-28
股市必读：之江生物（688317）4月27日披露最新机构调研信息
之江生物(688317)3月31日股东户数1.55万户，较上期增加13.72%
证券之星 · 04-24
之江生物(688317)3月31日股东户数1.55万户，较上期增加13.72%
图解之江生物年报：第四季度单季净利润同比增长95.70%
证券之星 · 04-24
图解之江生物年报：第四季度单季净利润同比增长95.70%
每周股票复盘：之江生物（688317）累计回购275万股耗资5787万
证券之星 · 04-05
每周股票复盘：之江生物（688317）累计回购275万股耗资5787万
之江生物（688317）披露2025年第三次以集中竞价交易方式回购公司股份的进展公告，4月3日股价下跌1.68%
证券之星 · 04-03
之江生物（688317）披露2025年第三次以集中竞价交易方式回购公司股份的进展公告，4月3日股价下跌1.68%
每周股票复盘：之江生物（688317）两产品获马来西亚认证
证券之星 · 03-22
每周股票复盘：之江生物（688317）两产品获马来西亚认证
之江生物（688317）披露公司产品获得马来西亚医疗器械管理局认证，3月19日股价下跌2.06%
证券之星 · 03-19
之江生物（688317）披露公司产品获得马来西亚医疗器械管理局认证，3月19日股价下跌2.06%
之江生物(688317.SH)：2项产品获得相关认证
智通财经 · 03-19
之江生物(688317.SH)：2项产品获得相关认证
之江生物：累计回购公司股份2065434股
证券日报 · 03-03
之江生物：累计回购公司股份2065434股
之江生物去年营收1.25亿元，已连续三年营收下滑、净利亏损
新京报 · 03-02
之江生物去年营收1.25亿元，已连续三年营收下滑、净利亏损
每周股票复盘：之江生物（688317）2025年净亏3430万
证券之星 · 03-01
每周股票复盘：之江生物（688317）2025年净亏3430万
之江生物发布2025年度业绩快报，亏损0.343亿元
证券之星 · 02-27
之江生物发布2025年度业绩快报，亏损0.343亿元
增持加码三优生物，之江生物深化“诊断+治疗”布局，业绩亏损泥潭待解
证券之星 · 02-27
增持加码三优生物，之江生物深化“诊断+治疗”布局，业绩亏损泥潭待解
之江生物（688317）披露2026年度日常关联交易预计公告，2月25日股价上涨0.43%
证券之星 · 02-25
之江生物（688317）披露2026年度日常关联交易预计公告，2月25日股价上涨0.43%
暂无数据
公司概况
公司名称：
上海之江生物科技股份有限公司
所属行业：
医药制造业
上市日期：
2021-01-18
主营业务：
上海之江生物科技股份有限公司的主营业务是分子诊断试剂和仪器设备的研发、生产和销售。公司的主要产品是分子诊断试剂、仪器设备。公司项目在上海市重点产品质量攻关成果中获得二等奖。
发行价格：
43.22
{"stockData":{"symbol":"688317","market":"SH","secType":"STK","nameCN":"之江生物","latestPrice":20.38,"timestamp":1778569200000,"preClose":21.45,"halted":0,"volume":4887143,"delay":0,"changeRate":-0.0499,"floatShares":192000000,"shares":192000000,"eps":-0.2279,"marketStatus":"已收盘","change":-1.07,"latestTime":"05-12 15:00:00","open":20.81,"high":21.05,"low":20.38,"amount":101000000,"amplitude":0.0312,"askPrice":20.4,"askSize":5,"bidPrice":20.38,"bidSize":93,"shortable":0,"etf":0,"ttmEps":-0.2279,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1778635800000},"marketStatusCode":5,"adr":0,"adjPreClose":21.45,"symbolType":"stock_kcb","openAndCloseTimeList":[[1778549400000,1778556600000],[1778562000000,1778569200000]],"highLimit":23.6,"lowLimit":19.31,"ibTradeSell":true,"ibTradeBuySell":false,"totalEquity":192157999,"isCdr":false,"pbRate":1.19,"roa":"--","roe":"--","epsLYR":-0.19,"committee":0.516022,"marketValue":3916000000,"turnoverRate":0.0254,"status":1,"afterMarket":{"amount":0,"volume":0,"close":20.38,"buyVolume":0,"sellVolume":0,"time":1778571237558,"indexStatus":"已收盘 05-12 15:30:00","preClose":21.45},"floatMarketCap":3916000000},"requestUrl":"/m/hq/s/688317/tweets","defaultTab":"tweets","newsList":[{"id":"2634414533","title":"每周股票复盘：之江生物（688317）将召开2025年年度股东会","url":"https://stock-news.laohu8.com/highlight/detail?id=2634414533","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634414533?lang=zh_cn&edition=full","pubTime":"2026-05-10 02:20","pubTimestamp":1778350820,"startTime":"0","endTime":"0","summary":"截至2026年5月8日收盘，之江生物报收于20.83元，较上周的19.5元上涨6.82%。本周关注点公司公告汇总：之江生物将于2026年5月14日召开2025年年度股东会，审议董事会工作报告、利润分配等议案。之江生物：关于召开2025年年度业绩说明会的公告上海之江生物科技股份有限公司将于2026年5月18日09:00-10:00通过上证路演中心网络互动方式召开2025年年度业绩说明会，介绍公司年度经营成果及财务状况。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051000000810.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633126691","title":"之江生物（688317）披露2025年第三次以集中竞价交易方式回购公司股份的进展公告，5月7日股价上涨2.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633126691","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633126691?lang=zh_cn&edition=full","pubTime":"2026-05-07 22:42","pubTimestamp":1778164937,"startTime":"0","endTime":"0","summary":"截至2026年5月7日收盘，之江生物报收于20.11元，较前一交易日上涨2.6%，最新总市值为38.64亿元。该股当日开盘19.6元，最高20.52元，最低19.56元，成交额达5749.27万元，换手率为1.49%。近日，之江生物发布《关于2025年第三次以集中竞价交易方式回购公司股份的进展公告》。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050700041569.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633342184","title":"之江生物（688317）披露2025年年度股东会会议资料，5月6日股价上涨0.51%","url":"https://stock-news.laohu8.com/highlight/detail?id=2633342184","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633342184?lang=zh_cn&edition=full","pubTime":"2026-05-06 18:52","pubTimestamp":1778064734,"startTime":"0","endTime":"0","summary":"截至2026年5月6日收盘，之江生物报收于19.6元，较前一交易日上涨0.51%，最新总市值为37.66亿元。该股当日开盘19.46元，最高19.9元，最低19.43元，成交额达3112.65万元，换手率为0.83%。近日，之江生物发布《2025年年度股东会会议资料》。公告显示，公司2025年年度股东会定于2026年5月14日召开，采用现场与网络投票相结合方式。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050600032699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632862599","title":"每周股票复盘：之江生物（688317）股东户数增13.72%，一季度净利降59.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2632862599","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632862599?lang=zh_cn&edition=full","pubTime":"2026-05-02 07:00","pubTimestamp":1777676451,"startTime":"0","endTime":"0","summary":"截至2026年4月30日收盘，之江生物报收于19.5元，较上周的20.23元下跌3.61%。本周，之江生物4月28日盘中最高价报20.32元。之江生物当前最新总市值37.47亿元，在医疗器械板块市值排名94/129，在两市A股市值排名4154/5200。业绩披露要点：一季度归母净利润-2551.02万元，同比下滑59.27%。股本股东变化股东户数变动截至2026年3月31日，之江生物股东户数为1.55万户，较2025年末增加1870户，增幅13.72%。户均持股由1.41万股降至1.24万股，户均持股市值为23.41万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026050200003762.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631596576","title":"之江生物(688317)3月31日股东户数1.55万户，较上期增加13.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2631596576","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631596576?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:43","pubTimestamp":1777455808,"startTime":"0","endTime":"0","summary":"证券之星消息，近日之江生物披露，截至2026年3月31日公司股东户数为1.55万户，较12月31日增加1870.0户，增幅为13.72%。在医疗器械行业个股中，之江生物股东户数低于行业平均水平，截至3月31日，医疗器械行业平均股东户数为2.2万户。从股价来看，2025年12月31日至2026年3月31日，之江生物区间跌幅为6.4%，在此期间股东户数增加1870.0户，增幅为13.72%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042900055431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631593699","title":"之江生物(688317.SH)发布一季度业绩，归母净亏损2551万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2631593699","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2631593699?lang=zh_cn&edition=full","pubTime":"2026-04-29 17:12","pubTimestamp":1777453968,"startTime":"0","endTime":"0","summary":"智通财经APP讯，之江生物(688317.SH)披露2026年第一季度报告，报告期公司实现营收2542万元，同比下降20.90%;归母净利润亏损2551万元;扣非净利润亏损2715万元。基本每股收益-0.15元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1436226.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"之江生物(688317.SH)发布一季度业绩，归母净亏损2551万元","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630434395","title":"股市必读：之江生物（688317）4月27日披露最新机构调研信息","url":"https://stock-news.laohu8.com/highlight/detail?id=2630434395","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2630434395?lang=zh_cn&edition=full","pubTime":"2026-04-28 05:52","pubTimestamp":1777326757,"startTime":"0","endTime":"0","summary":"截至2026年4月27日收盘，之江生物报收于20.06元，下跌0.84%，换手率1.01%，成交量1.93万手，成交额3853.43万元。来自机构调研要点：公司目前不存在直接的ST风险，管理层正通过聚焦IVD主业、优化产品结构、拓展海内外市场等措施改善基本面。来自机构调研要点：公司坚持诊断与治疗并重的发展路径，诊断业务为基本盘，创新药作为未来增长期权协同发展。机构调研要点公司截至目前共开展五次股份回购。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042800015488.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629814934","title":"之江生物(688317)3月31日股东户数1.55万户，较上期增加13.72%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629814934","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629814934?lang=zh_cn&edition=full","pubTime":"2026-04-24 17:31","pubTimestamp":1777023073,"startTime":"0","endTime":"0","summary":"证券之星消息，近日之江生物披露，截至2026年3月31日公司股东户数为1.55万户，较12月31日增加1870.0户，增幅为13.72%。在医疗器械行业个股中，之江生物股东户数低于行业平均水平，截至3月31日，医疗器械行业平均股东户数为2.18万户。从股价来看，2025年12月31日至2026年3月31日，之江生物区间跌幅为6.4%，在此期间股东户数增加1870.0户，增幅为13.72%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400052624.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629514758","title":"图解之江生物年报：第四季度单季净利润同比增长95.70%","url":"https://stock-news.laohu8.com/highlight/detail?id=2629514758","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2629514758?lang=zh_cn&edition=full","pubTime":"2026-04-24 00:57","pubTimestamp":1776963456,"startTime":"0","endTime":"0","summary":"证券之星消息，之江生物2025年年报显示，当年度公司主营收入1.25亿元，同比下降30.13%；归母净利润-3429.76万元，同比上升73.09%；扣非净利润-4910.98万元，同比上升61.71%；其中2025年第四季度，公司单季度主营收入3438.58万元，同比下降16.28%；单季度归母净利润-491.97万元，同比上升95.7%；单季度扣非净利润-1185.82万元，同比上升89.12%；负债率11.02%，投资收益382.13万元，财务费用-3554.1万元，毛利率64.15%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026042400002387.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2625199346","title":"每周股票复盘：之江生物（688317）累计回购275万股耗资5787万","url":"https://stock-news.laohu8.com/highlight/detail?id=2625199346","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2625199346?lang=zh_cn&edition=full","pubTime":"2026-04-05 03:01","pubTimestamp":1775329273,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，之江生物报收于20.52元，较上周的19.26元上涨6.54%。本周，之江生物4月2日盘中最高价报21.72元。之江生物当前最新总市值39.43亿元，在医疗器械板块市值排名88/129，在两市A股市值排名3874/5193。截至2026年3月31日，累计回购股份2,752,883股，占公司总股本的1.43%，已支付金额57,866,984.16元。2026年3月单月回购687,449股，支付资金13,378,001.95元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040500000815.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2624633256","title":"之江生物（688317）披露2025年第三次以集中竞价交易方式回购公司股份的进展公告，4月3日股价下跌1.68%","url":"https://stock-news.laohu8.com/highlight/detail?id=2624633256","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2624633256?lang=zh_cn&edition=full","pubTime":"2026-04-03 22:24","pubTimestamp":1775226262,"startTime":"0","endTime":"0","summary":"截至2026年4月3日收盘，之江生物报收于20.52元，较前一交易日下跌1.68%，最新总市值为39.43亿元。之江生物于2026年4月3日发布《关于2025年第三次以集中竞价交易方式回购公司股份的进展公告》。截至2026年3月31日，累计回购股份2,752,883股，占公司总股本的1.43%，已支付金额57,866,984.16元。2026年3月单月回购687,449股，支付资金13,378,001.95元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026040300043582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2621799169","title":"每周股票复盘：之江生物（688317）两产品获马来西亚认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2621799169","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2621799169?lang=zh_cn&edition=full","pubTime":"2026-03-22 03:00","pubTimestamp":1774119638,"startTime":"0","endTime":"0","summary":"截至2026年3月20日收盘，之江生物报收于19.08元，较上周的19.88元下跌4.02%。本周，之江生物3月17日盘中最高价报20.11元。本周关注点公司公告汇总：之江生物两项RNA提取试剂获马来西亚医疗器械认证，有效期均至2031年。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026032200000806.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620243092","title":"之江生物（688317）披露公司产品获得马来西亚医疗器械管理局认证，3月19日股价下跌2.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2620243092","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620243092?lang=zh_cn&edition=full","pubTime":"2026-03-19 17:10","pubTimestamp":1773911417,"startTime":"0","endTime":"0","summary":"截至2026年3月19日收盘，之江生物报收于19.47元，较前一交易日下跌2.06%，最新总市值为37.41亿元。近日，上海之江生物科技股份有限公司发布《关于自愿披露公司产品获得相关认证的公告》。公告显示，公司两项产品“Viral RNA Isolation Kit ”和“Viral RNA Extraction Kit”近期获得马来西亚医疗器械管理局认证，认证有效期分别为2026年3月6日至2031年3月5日、2026年2月27日至2031年2月26日，适用范围为临床样本中核酸的提取，可在马来西亚及认可该认证的国家销售。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026031900027622.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","09996","BK1222","BK1583","BK1100","159883","688317","09997"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620178352","title":"之江生物(688317.SH)：2项产品获得相关认证","url":"https://stock-news.laohu8.com/highlight/detail?id=2620178352","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2620178352?lang=zh_cn&edition=full","pubTime":"2026-03-19 15:42","pubTimestamp":1773906164,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 之江生物(688317.SH)发布公告，公司2项产品于近期获得相关认证，分别为：“Viral RNA Isolation Kit (Preloaded for Auto-Extraction) 核酸提取试剂(预装用于自动化提取)”、“ViralRNAExtraction Kit 核酸提取试剂”。上述产品获得认证后，可在马来西亚和认可马来西亚认证的国家进行销售，进一步提升了公司的国际化竞争力，对于公司扩充海外销售产品品类及国际业务拓展具有积极作用。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1415883.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"之江生物(688317.SH)：2项产品获得相关认证","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616239303","title":"之江生物：累计回购公司股份2065434股","url":"https://stock-news.laohu8.com/highlight/detail?id=2616239303","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616239303?lang=zh_cn&edition=full","pubTime":"2026-03-03 20:39","pubTimestamp":1772541540,"startTime":"0","endTime":"0","summary":"证券日报网讯 3月3日，之江生物发布公告称，截至2026年2月28日，公司通过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份2，065，434股，占公司当前总股本192，157，999股的比例为1.07%，回购成交的最高价为23.49元/股，最低价为19.58元/股，支付的资金总额为人民币44，488，982.21元（不含印花税、交易佣金等交易费用）。本次回购股份符合相关法律法规的规定及公司的回购股份方案。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-03/doc-inhptkrh7466657.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-03/doc-inhptkrh7466657.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0239","688317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616333278","title":"之江生物去年营收1.25亿元，已连续三年营收下滑、净利亏损","url":"https://stock-news.laohu8.com/highlight/detail?id=2616333278","media":"新京报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616333278?lang=zh_cn&edition=full","pubTime":"2026-03-02 18:59","pubTimestamp":1772449140,"startTime":"0","endTime":"0","summary":"至此，之江生物已经连续三年营收下滑，净利亏损。2020年之前，之江生物的营业收入保持稳定增长，但尚不足3亿元。之江生物的业绩也随之大幅提升，2020年，其营业收入分别为20.52亿元，同比增长692.72%；同期，归母净利润分别为9.32亿元，同比增长1708.96%。2021年及2022年，之江生物的营收分别为20.19亿元、23.26亿元，归母净利润分别为7.59亿元、7.63亿元。新冠疫情红利消退后，之江生物业绩出现大幅下滑。","market":"hk","thumbnail":"https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/3/wangl882026321849162928526.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80","type":0,"news_type":0,"thumbnails":["https://media.bjnews.com.cn/fz/html/AttachPubDev/2026/3/wangl882026321849162928526.jpg?x-oss-process=image/resize,m_lfit,w_365/quality,q_80"],"rights":{"source":"highlight_bjnews","url":"https://www.bjnews.com.cn/detail/1772449155168645.html","rn_cache_url":null,"customStyle":"handleCustomStyle(customStyle, ThemeStyle, getFont(fontSize))","selectors":"#main .nleft","filters":".ntit, .attitude","directOrigin":true},"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bjnews.com.cn/detail/1772449155168645.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_bjnews","symbols":["688317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2616784503","title":"每周股票复盘：之江生物（688317）2025年净亏3430万","url":"https://stock-news.laohu8.com/highlight/detail?id=2616784503","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2616784503?lang=zh_cn&edition=full","pubTime":"2026-03-01 03:14","pubTimestamp":1772306051,"startTime":"0","endTime":"0","summary":"截至2026年2月27日收盘，之江生物报收于21.07元，较上周的20.93元上涨0.67%。本周，之江生物2月25日盘中最高价报21.26元。本周关注点业绩披露要点：之江生物2025年净亏3430.38万元，同比减亏9315.83万元。公司公告汇总：之江生物预计2026年日常关联交易总额800万元。公司公告汇总：之江生物拟使用不超过8.6亿元闲置募集资金进行现金管理。业绩披露要点之江生物近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润亏损0.343亿元，同比增长73.09%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030100001246.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614833108","title":"之江生物发布2025年度业绩快报，亏损0.343亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2614833108","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614833108?lang=zh_cn&edition=full","pubTime":"2026-02-27 17:06","pubTimestamp":1772183168,"startTime":"0","endTime":"0","summary":"证券之星消息，之江生物近日即将发布2025年年报，根据2月27日发布的业绩快报，归属净利润亏损0.343亿元，同比增长73.09%。报告期内，公司主要因集采政策陆续执行导致销售价格下降、自产试剂产品增值税税率调整为 13%和产品销量结构的变化等原因导致收入下降；财务收益的下降和汇兑损益减少等原因导致经营业绩亏损。公司成本费用管控措施落地见效，资产减值损失同比减少，2025年同比去年经营情况实现减亏。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022700027555.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614874198","title":"增持加码三优生物，之江生物深化“诊断+治疗”布局，业绩亏损泥潭待解","url":"https://stock-news.laohu8.com/highlight/detail?id=2614874198","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614874198?lang=zh_cn&edition=full","pubTime":"2026-02-27 16:09","pubTimestamp":1772179793,"startTime":"0","endTime":"0","summary":"此番增持是之江生物落实“诊断+治疗”全产业链布局的重要举措。增持三优生物，巩固全产业链布局之江生物近日通过公司公众号发布信息，宣布完成对三优生物的新一轮战略增持。对于此次对三优生物的战略增持，之江生物表示，基于技术互补性与产业协同逻辑，进一步整合优势资源，巩固并深化在精准医疗下“诊断+治疗”的全产业链布局。2024年，之江生物营收规模缩减至1.79亿元，归属净利润亏损1.28亿元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2026022700025195.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688317","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2614503681","title":"之江生物（688317）披露2026年度日常关联交易预计公告，2月25日股价上涨0.43%","url":"https://stock-news.laohu8.com/highlight/detail?id=2614503681","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2614503681?lang=zh_cn&edition=full","pubTime":"2026-02-25 22:54","pubTimestamp":1772031254,"startTime":"0","endTime":"0","summary":"截至2026年2月25日收盘，之江生物报收于21.14元，较前一交易日上涨0.43%，最新总市值为40.62亿元。近日，之江生物发布《关于2026年度日常关联交易预计的公告》。公告显示，公司于2026年2月24日召开第五届董事会第十八次会议，审议通过《关于2026年度日常关联交易预计的议案》，关联董事邵俊斌及倪卫琴对部分交易回避表决。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022500038429.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688317"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1778631222913,"stockEarnings":[{"period":"1week","weight":0.0451},{"period":"1month","weight":-0.0258},{"period":"3month","weight":-0.0382},{"period":"6month","weight":-0.1061},{"period":"1year","weight":0.2174},{"period":"ytd","weight":0.0104}],"compareEarnings":[{"period":"1week","weight":0.0249},{"period":"1month","weight":0.0573},{"period":"3month","weight":0.02},{"period":"6month","weight":0.0459},{"period":"1year","weight":0.2509},{"period":"ytd","weight":0.0619}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"上海之江生物科技股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"15499人(较上一季度增加13.72%)","perCapita":"12398股","listingDate":"2021-01-18","address":"上海市浦东新区张江高科技产业东区瑞庆路528号20幢乙号1层、21幢甲号1层","registeredCapital":"19215万元","survey":" 上海之江生物科技股份有限公司的主营业务是分子诊断试剂和仪器设备的研发、生产和销售。公司的主要产品是分子诊断试剂、仪器设备。公司项目在上海市重点产品质量攻关成果中获得二等奖。","listedPrice":43.22},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.2","shortVersion":"4.42.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"之江生物(688317)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供之江生物(688317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"之江生物,688317,之江生物股票,之江生物股票老虎,之江生物股票老虎国际,之江生物行情,之江生物股票行情,之江生物股价,之江生物股市,之江生物股票价格,之江生物股票交易,之江生物股票购买,之江生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"之江生物(688317)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供之江生物(688317)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}